AALM

A major new JAMA Psychiatry meta-analysis just concluded that psychedelic therapy is no more effective than SSRIs for depression. Most people in the psychedelic space will read that as bad news. I think they're missing the more important question it raises. If the efficacy is roughly equal, the real question becomes the one psychiatry has been avoiding for decades: Which treatment causes less harm? The paper makes a smart argument. Since psychedelic trials are effectively always open-label, they should be compared against open-label SSRI trials rather than blinded ones. When you do that, the efficacy gap disappears. Both produce roughly the same level of improvement. I take the meta-analysis seriously. But the conversation to open up is not the one I'm seeing. If efficacy is comparable, why aren't we talking about the harm? SSRIs have been on the market for ~40 years. In that time, we've accumulated a staggering catalog of iatrogenic damage. Between 40-60% of patients experience emotional blunting: that flat, muted quality where you lose access to joy, connection, creativity, and desire. Post-marketing data show sexual dysfunction rates as high as 75%, and we now have growing evidence that these effects can persist months or years after discontinuation. The FDA carries a black box suicide warning for patients under 25. Up to half of patients who try to stop SSRIs experience discontinuation syndrome, sometimes severe enough to require hospitalization. These are not edge cases. These are the known costs of the standard of care. Now compare that to the psychedelic safety profile across not 40 years, but thousands. Psilocybin use in Mesoamerica stretches back at least 2,000 years. Ayahuasca traditions in the Amazon go back centuries. The Eleusinian Mysteries in ancient Greece likely involved an ergot-derived psychedelic and ran continuously for nearly 2,000 years. Nassim Taleb would call this the Lindy Effect: the longer something has survived, the longer you can expect it to keep surviving. Psychedelics have passed a civilizational stress test that SSRIs haven't begun to face. Modern clinical data confirms it. Psilocybin has no known lethal dose, no physical dependence, and no discontinuation syndrome. The most common adverse effects are transient anxiety and temporary headaches. Serious adverse events across the major trials have been rare and manageable within a supported therapeutic container. So if JAMA Psychiatry tells us the efficacy is comparable, shouldn't the next question be obvious? One treatment requires daily dosing for months or years, blunts your emotional range, disrupts your sex life, creates dependence, and carries a black box suicide warning. The other involves one to three sessions, has been used safely for millennia, and the most common side effect is that you might erupt into an emotional catharsis. What would an honest risk-benefit analysis look like if we actually weighed the full harm profile?